GENE ONLINE|News &
Opinion
Blog

Vertex Pharmaceuticals
Vertex and Lonza Collaborate to Revolutionize Type 1 Diabetes Treatment
2023-06-29
Vertex and CRISPR Collaborate Again with $330 Million Diabetes Gene Editing Deal
2023-03-28
Vertex’s Orkambi Racks Up Another Approval For Cystic Fibrosis
2022-09-05
Verve and Vertex Agree to Co-Develop In Vivo Gene Editing Program for Liver Disease
2022-07-21
Vertex Signs $700 Million worth CRISPR Pact with Jennifer Doudna Co-founded Gene Editing Firm
2021-10-26
Vertex Inks $1.2B Pact with Feng Zhang Cofounded Startup to Develop Gene Therapies for Blood Diseases
2021-08-25
Vertex to Reap Majority Profits from Gene Editing Deal with CRISPR Therapeutics
2021-04-21
FDA Approves 3 Cystic Fibrosis Drugs of Vertex for Patients with Rare Mutations
2020-12-24
CRISPR Therapeutics Scores Prestigious Grant for Advancing Gene Therapies for HIV
2020-12-16
CRISPR Gene-Edited Therapy CTX001 Raises Hopes for Sickle Cell Disease and β-Thalassemia Cures
2020-12-07
Vertex Bags EU Approval for Cystic Fibrosis Treatment in Children Aged 6-11 Years
2020-11-29
With its AAT Deficiency Therapy Biting the Dust, Vertex Pins Hope on Second Drug
2020-10-16
CRISPR, Vertex’s Gene Editing Based Therapy, CTX001 Prospers in Hemoglobinopathy Trials
2020-06-18
An Outlook on the Evolution of Cystic Fibrosis Care
2020-05-13
LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top